Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been recommended by the National ...

Bret Hulick was in his second year of medical school at LECOM in Erie, analyzing the case of a 24-year-old colon cancer ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

On April 8, the FDA approved use of this drug combination for adults and children age 12 and older whose colorectal cancer has metastasized ... Results showed the immunotherapy combination led ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

Researchers retrospectively analysed data from 368 patients with MSI-H colon cancer across two academic centres. Patients ...

Real-world data show that immunotherapy leads to better overall ... association between higher dairy intake and lower colorectal cancer risk.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Portuguese researchers working to advance colorectal cancer treatment have discovered a new type of white blood cell that could open the door to more ...

A new implant safely triggers potent immune responses against hard-to-treat cancers showing "promise" for pancreatic and ...